Search for a way to improve the serum albumin binding function and the functional state of the liver when hypertension combined with non-alcoholic fatty liver disease
Keywordshypertension, non-alcoholic fatty liver disease, serum albumin binding function, Antral, blood proteins, functional state of the liver
Recently, there has been a significant increase in interest in research on hypertension (HT), primarily due to its high prevalence. The interest in studying this problem is also exacerbated by the often insufficient effectiveness of existing treatments. The effect of concomitant pathologies on HT, in particular non-alcoholic fatty liver disease (NAFLD), remains poorly understood.
The aim of the study – to evaluate the changes in the serum albumin binding function (SABF) and its relationship with the biochemical parameters of the blood when HT and HT combined with NAFLD and to suggest ways of medical correction of the detected disorders.
Material and methods. 76 individuals with stage 2 HT with degree 2–3 arterial hypertension were examined. They were divided into two groups. Group 1 included 28 patients with HT without concomitant diseases who received basic hypertension therapy, and group 2 included patients with concomitant NAFLD. The latter in turn was divided into two subgroups: 2a – 27 patients who in addition to basic HT therapy received additional Antral hepatoprotector 200 mg three times a day for 2 months, and 2b – 21 patients who received only basic HT therapy. All of them underwent a standard clinical examination, as well as SABF, protein fractions, and liver function indicators. The comparison group consisted of 25 healthy individuals, comparable in age and sex.
Results and Discussion. Patients in group 1 showed moderate changes in the functional state of the liver, but they did not exceed the norm, patients in group 2 – a significant decrease in SABF, as well as protein metabolism (decrease in total protein, albumin, albumin-globulin ratio and increase globulins) and liver function (increased activity of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltranspeptidase, thymol levels, alkaline phosphatase and total bilirubin). After treatment, the majority of patients in subgroup 2 had a statistically significant increase in SABF and a quantitative improvement in protein fractions and functional state of the liver. In subgroup 2-b, where hepatoprotective treatment was not performed, significant changes in most indicators did not occur. The results may be related to the positive effect of the drug on the liver, which leads to improved functional status of hepatocytes and their protein-synthesizing ability. In subgroup 2 b, where hepatoprotective treatment was not performed, significant changes in most indicators did not occur. The results may be related to the positive effect of the drug on the liver leading to improved functional status of hepatocytes and their protein-synthesizing ability.
Conclusions. Changes of the functional state of the liver are observed when HT without concomitant pathology. HT with NAFLD is accompanied by a significant decrease in SABF, changes in protein metabolism and the functional state of the liver. Prescribing Antral to such patients helps to increase SABF, normalize protein metabolism and improve the functional state of the liver.
Lashkul ZV. Osoblyvosti epidemiologhiji arterialjnoji ghipertenziji ta jiji uskladnenj na reghionaljnomu rivni z 1999 po 2013 roky. [Features of the epidemiology of hypertension and its deterioration at the regional level from 1999 to 2013]. Suchasni medychni tekhnologhiji. 2014;2:134.
Mills K, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020;16(4):223-237. doi: 10.1038/s41581-019-0244-2.
Skljarov JeJa, Aksentijchuk KhB, Kurljak NV. Monitoryngh porushenj funkciji pechinky u pacijentiv z nealkogholjnoju zhyrovoju khvoroboju pechinky na tli metabolichnogho syndromu. [Monitoring of liver dysfunction in patients with non-alcoholic fatty liver disease on the background of metabolic syndrome]. Ghepatologhija. 2015;1:34-41.
Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can. J. Cardiol. 2017;33(5):557-576. doi:10.1016/j.cjca.2018.02.022
Skybchyk VA, Vojtovych MO. Nealkogholjna zhyrova khvoroba pechinky: suchasna diaghnostyka. [Non-alcoholic fatty liver disease: modern diagnosis]. Ghepatologhija. 2015;1:52-56.
Kirijenko VT, Potij VV. Efektyvnistj antralju u khvorykh na khronichnyj ghepatyt C. [The effectiveness of antral in patients with chronic hepatitis C]. Visnyk naukovykh doslidzhenj. 2015;3:28-30.
Polunina TE. Nealkogol`naya zhirovaya bolezn` pecheni. [Non-alcoholic fatty liver disease]. Mul`tifaktornaya patologiya. 2013;13-14:11-13.
Andrejchyn SM, Skirak ZS. Vplyv ghlutarghinu na zv'jazuvaljnu funkciju syrovatkovogho aljbuminu ta inshi pokaznyky funkcionaljnogho stanu pechinky pry ghostromu toksychnomu ghidrazynovomu ghepatyti. [Effect of glutargine on serum albumin binding function and other indicators of liver function in acute toxic hydrazine hepatitis]. Medychna ta klinichna khimija. 2014;4:66-69.
Skirak ZS. Pokaznyky endoghennoji intoksykaciji ta lipoperoksydaciji v dynamici ghostrogho toksychnogho tetrakhlormetanovogho ghepatytu.[ Indicators of endogenous intoxication and lipoperoxidation in the dynamics of acute toxic carbon tetrachloride hepatitis]. Infekcijni khvoroby. 2014;3:89-92.
Skirak ZS. Porushennja zv'jazuvaljnoji funkciji syrovatkovogho aljbuminu pry toksychnykh ghepatytakh. [Impaired serum albumin binding in toxic hepatitis]. [dysertacija]. Ternopilj: Ternop. nac. med. un-t; 2016.161 s.
Bellentani S. The epidemiology of non‐alcoholic fatty liver disease. Liver international. 2017;37:81-84. doi: 10.1111/liv.13299
Zvyaginczeva TD, Chernobaj AI. Primenenie preparata Antral` v lechenii nealkogol`nogo steatogepatita: nastoyashhee i budushhee. [The use of Antral in the treatment of non-alcoholic steatohepatitis: present and future]. Chelovek i Lekarstvo – Kazakhstan. 2016;17(78):84.
Babak OYa, Fadeenko GD, Kolesnikova EV. Opy`t primeneniya preparata Antral` v sostave kompleksnoj terapii nealkogol`noj zhirovoj bolezni pecheni. [Experience in the use of the drug Antral in the complex therapy of non-alcoholic fatty liver disease]. Consilium Medicum Ukraina, tom 4. 2010;5:22.
Borysov SO, Kostjev FI, Borysov OV. Detoksykacijnyj vplyv preparatu Antralj na perebigh obstruktyvnoji–nefropatiji. [Detoxifying effect of Antral on the course of obstructive nephropathy]. Zdorovj'e muzhchynы. 2013;4:193-193.
How to Cite
Copyright (c) 2022 Yurii Dzordzo, Serhiy Andreychyn
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 187
Number of citations: 0